EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Personalized Genome‐Scale Modeling Reveals Metabolic Perturbations in Fibroblasts of Methylmalonic Aciduria Patients

Almut Heinken iD, Hussein Awada, Vito R T Zanotelli, D Sean Froese iD, Rosa-Maria Guéant-Rodriguez, Jean-Louis Guéant

Journal of Inherited Metabolic Disease · 2025-09 · 48 (5)

DOI: 10.1002/jimd.70077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 11.08.2025. Verfasst von Almut Heinken und 5 weiteren Autor:innen. Beteiligte Einrichtung: UMRS Inserm 1256 nGERE (Nutrition-Genetics-Environmental Risks), Institute of Medical Research (Pôle BMS), University of Lorraine, Nancy, France. Hauptthemen laut MEDLINE: Amino Acid Metabolism, Inborn Errors, Fibroblasts. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, University of Zurich ITNERARE-Innovative Therapies in Rare Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cobalamin (vitamin B12) is an essential cofactor for two human enzymes, methionine synthase and methylmalonyl‐CoA mutase. Inborn errors of cobalamin metabolism (IECMs) are inherited genetic defects resulting in improper transport, modification, or utilization of cobalamin and include inherited methylmalonic acidurias, a group of IECMs most frequently caused by a defect in the methylmalonyl‐CoA mutase enzyme. Here, we performed genome‐scale modeling of IECMs to gain insight into their metabolic perturbations. First, we simulated deficiencies in 11 IECM‐related genes and demonstrated that they cluster based on impaired metabolic pathways. Next, we leveraged RNA sequencing data from fibroblasts of 202 individuals with methylmalonic aciduria and 19 unaffected controls to construct and interrogate personalized metabolic models. Finally, we analyzed fluxes differing between patients depending on reported symptom presentation. Our findings reveal that (i) metabolic pathways including fatty acid metabolism and heme biosynthesis have reduced flux in IECMs, (ii) in personalized simulations, succinate and fumarate production and heme biosynthesis are impaired, especially in methylmalonyl‐CoA mutase deficiency, (iii) one‐carbon metabolism reactions such as serine hydroxymethyltransferase and folylglutamate synthase have reduced flux in all individuals with methylmalonic aciduria, and (iv) specific metabolic pathways are up‐ or down‐regulated according to symptoms, including failure to thrive and hematological abnormalities, and treatments, such as antibiotics and protein restriction. Overall, our study delineates metabolic pathways perturbed in IECMs. In future applications, our modeling framework could be applied to other rare genetic diseases or used to predict personalized therapeutic or dietary interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amino Acid Metabolism, Inborn ErrorsFibroblastsHumansVitamin B 12Metabolic Networks and PathwaysMethylmalonyl-CoA MutaseVitamin B 12 DeficiencyMaleModels, BiologicalFemalePrecision Medicine

Substanzen

Vitamin B 12Methylmalonyl-CoA Mutase

Autor:innen und Institutionen

  • UMRS Inserm 1256 nGERE (Nutrition-Genetics-Environmental Risks), Institute of Medical Research (Pôle BMS), University of Lorraine, Nancy, France.
  • Division of Metabolism and Children's Research Center, University Children's Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • National Reference Medical Biology Laboratory (LBMR) for Inherited Metabolic Diseases, Biochemistry-Molecular Biology-Nutrition Laboratory, University Regional Hospital of Nancy, Nancy, France.
  • Department of Hepato-Gastroenterology, National Reference Center for Inherited Metabolic Diseases, University Regional Hospital of Nancy, Nancy, France.
  • Joan Klein Jacobs Center for Precision Nutrition and Health, Cornell University, Ithaca, New York, USA.

ORCID-Profile: Almut Heinken, D Sean Froese

Förderung

  • Agence Nationale de la Recherche
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • University of Zurich ITNERARE-Innovative Therapies in Rare Diseases

Zitieren

APA

Heinken, A., Awada, H., Zanotelli, V. R. T., Froese, D. S., Guéant-Rodriguez, R. M., & Guéant, J. L. (2025). Personalized Genome‐Scale Modeling Reveals Metabolic Perturbations in Fibroblasts of Methylmalonic Aciduria Patients. Journal of Inherited Metabolic Disease, 48(5). https://doi.org/10.1002/jimd.70077

Vancouver

Heinken A, Awada H, Zanotelli VRT, Froese DS, Guéant-Rodriguez RM, Guéant JL. Personalized Genome‐Scale Modeling Reveals Metabolic Perturbations in Fibroblasts of Methylmalonic Aciduria Patients. Journal of Inherited Metabolic Disease. 2025;48(5). doi:10.1002/jimd.70077

BibTeX
@article{Heinken2025,
  author = {Heinken, Almut and Awada, Hussein and Zanotelli, Vito R T and Froese, D Sean and Guéant-Rodriguez, Rosa-Maria and Guéant, Jean-Louis},
  title = {Personalized Genome‐Scale Modeling Reveals Metabolic Perturbations in Fibroblasts of Methylmalonic Aciduria Patients},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  volume = {48},
  number = {5},
  doi = {10.1002/jimd.70077}
}
Kostenlos starten →